{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:33:21Z","timestamp":1794573201729,"version":"4.9.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":133,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.gastha.2025.100709","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:17:34Z","timestamp":1747739854000},"page":"100709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Real-World Experience With Resmetirom: Tolerability and Access"],"prefix":"10.1016","volume":"4","author":[{"given":"Sameera","family":"Shuaibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Tobal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruona","family":"Ebiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Ozoral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6113-4972","authenticated-orcid":false,"given":"George","family":"Therapondos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.gastha.2025.100709_bib1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.gastha.2025.100709_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"10.1016\/j.gastha.2025.100709_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ueg2.12525","article-title":"Therapeutic management of metabolic dysfunction associated steatotic liver disease","volume":"12","author":"Zeng","year":"2024","journal-title":"United Eur Gastroenterol J"},{"issue":"6","key":"10.1016\/j.gastha.2025.100709_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.gastha.2025.100709_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.gastha.2025.100709_bib6","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.gastha.2025.100709_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70242-8","article-title":"Efficacy and safety of resmetirom, a selective thyroid hormone receptor-\u03b2 agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"14","author":"Suvarna","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.gastha.2025.100709_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572325000962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572325000962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T07:05:12Z","timestamp":1761375912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572325000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"alternative-id":["S2772572325000962"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2025.100709","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Real-World Experience With Resmetirom: Tolerability and Access","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2025.100709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}],"article-number":"100709"}}